Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To determine the long-term safety and efficacy of a dose range of safinamide of 50-200 mg/day, p.o., compared to placebo, as add-on therapy in patients with early idiopathic Parkinson's disease who are currently receiving a stable dose of a single dopamine (DA) agonist.
Critère d'inclusion
- Parkinson's disease